We are live on ! Find out more

Beam Therapeutics

BEAM

Market cap $3.06B

29.66 USD

+0.20

0.68%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

30.37

+0.71

2.39%

1 day

0.68%

5 days

2.91%

1 month

4.62%

3 months

-9.68%

6 months

8.09%

Year to date

9.29%

1 year

59.98%

5 years

-73.84%

10 years

58.19%

About: Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Employees: 540

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 44.4%

Neutral 38.9%

Negative 16.7%

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam's commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Zacks Investment Research

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Zacks Investment Research

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus

Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus

Zacks Investment Research

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1 per share a year ago.

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics: A Valuation With Upside Left

Beam Therapeutics offers compelling upside, with a $2.64B market cap and a promising gene-editing pipeline spanning hematology and liver-targeted diseases. Lead programs Risto-cel, BEAM-302, and BEAM-301 demonstrate superior or competitive efficacy and safety profiles versus key competitors, supporting significant commercial potential. BEAM's $1.2B liquidity provides a cash runway well into 2029, with additional revenue from collaborations, notably with Eli Lilly and Pfizer.

Beam Therapeutics: A Valuation With Upside Left

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026, taking place September 5–9, 2026, in Barcelona, Spain.

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

The Motley Fool

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?

Cathie Wood continues adding shares of Beam Therapeutics. Clinical milestones could transform Beam into a commercial biotech.

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?

Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable

Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.

Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable

See News Rankings

Price charts implemented using Lightweight Charts™